Hydroxychloroquine is a disease-modifying antirheumatic drug (DMARD) that works by dialing down the overactive immune response behind rheumatoid arthritis. It reduces joint pain, swelling, and stiffness, and when used as part of a combination regimen, it helps slow the progression of joint damage over time. It’s one of the oldest and most widely prescribed RA medications, valued for its mild side effect profile and additional benefits for heart health.
How It Works in Your Body
Rheumatoid arthritis is driven by an immune system that mistakenly attacks the tissue lining your joints. Hydroxychloroquine interrupts this process at a cellular level by accumulating inside lysosomes, the small compartments your immune cells use to break down and process material. Once inside, the drug raises the pH of these compartments, making them less acidic. That matters because the enzymes responsible for processing proteins and triggering immune signals depend on an acidic environment to function.
With those compartments disrupted, your immune cells can’t properly activate certain inflammation-triggering pathways. Specifically, the drug interferes with toll-like receptors, sensors that normally detect threats and tell immune cells to release inflammatory chemicals. By blocking the downstream chain of signals from these receptors, hydroxychloroquine reduces the production of the inflammatory molecules that cause joint swelling, pain, and tissue destruction. Think of it less as a painkiller and more as a slow-acting brake on the immune process fueling the disease.
How Long It Takes to Work
Hydroxychloroquine is not a quick fix. Most people begin to notice improvement in joint stiffness and swelling somewhere between 2 and 6 months after starting the medication. Full therapeutic benefit can take even longer. In one study comparing combination RA treatments, the median time to a meaningful response in a hydroxychloroquine-containing regimen was 11 months. This slow onset is why rheumatologists often call it a “slow-acting” drug and may prescribe other medications alongside it to bridge the gap while it builds up in your system.
Its Role in Combination Therapy
Hydroxychloroquine is rarely used alone for moderate to severe RA. Its greatest strength shows up in combination with other DMARDs. The best-known regimen is “triple therapy,” which pairs hydroxychloroquine with methotrexate and sulfasalazine. A landmark trial published in the New England Journal of Medicine found that 77 percent of patients on all three drugs achieved and maintained at least 50 percent improvement over two years. That compared to just 33 percent for patients on methotrexate alone and 40 percent for those on sulfasalazine plus hydroxychloroquine without methotrexate.
Triple therapy remains a first-line option for RA that doesn’t respond adequately to methotrexate by itself. It’s often tried before moving to biologic drugs, which are more expensive and carry different risks. Hydroxychloroquine’s contribution to the combination appears to be its complementary mechanism: it targets a different part of the immune cascade than methotrexate or sulfasalazine, so together they suppress inflammation more thoroughly than any single drug.
On its own, hydroxychloroquine is less potent at preventing the bone erosions that cause permanent joint damage. In one 48-week trial comparing hydroxychloroquine to sulfasalazine, the hydroxychloroquine group showed significantly more joint erosion on X-rays. This is a key reason rheumatologists pair it with stronger drugs rather than relying on it as a standalone treatment for erosive disease.
Cardiovascular Benefits
People with rheumatoid arthritis face a higher risk of heart disease, partly because chronic inflammation accelerates the buildup of plaque in blood vessels. Hydroxychloroquine appears to help on this front. A study of RA patients found that those taking the drug consistently had significantly lower total cholesterol, LDL (“bad” cholesterol), and triglycerides compared to those who never took it. Their HDL (“good” cholesterol) was also higher. The average differences were meaningful: LDL dropped by about 9 mg/dL, triglycerides by nearly 17 mg/dL, and HDL rose by almost 8 mg/dL.
These lipid improvements are a notable bonus in a population already predisposed to cardiovascular problems. While no large randomized trial has confirmed that this translates directly into fewer heart attacks or strokes, the cholesterol-lowering effect is consistent across studies and adds to the drug’s overall value in long-term RA management.
Common Side Effects
Hydroxychloroquine is generally one of the best-tolerated DMARDs. The most frequent complaints are gastrointestinal: nausea, diarrhea, stomach pain, vomiting, and loss of appetite. Taking the medication with food or milk reduces these symptoms for most people. Some users also report headaches, ringing in the ears, or changes in hair color or texture.
Serious allergic reactions are uncommon but possible. Signs include hives, skin blisters, facial swelling, or difficulty breathing. These require immediate medical attention.
Eye Health and Screening
The side effect that gets the most attention is retinal toxicity. Hydroxychloroquine can, over years of use, damage the retina in a way that affects central vision. The risk is low in the first five years of treatment but increases with longer use, higher doses, and kidney problems.
Current guidelines from the American Academy of Ophthalmology recommend a baseline eye exam soon after starting the drug, including retinal imaging and a specialized scan called OCT (optical coherence tomography) along with fundus autofluorescence imaging. These tests establish a reference point so any future changes can be detected early. After the baseline, annual screening is recommended, though it can be deferred during the first five years if you have no major risk factors like kidney disease or high dosing.
The key to preventing vision problems is catching retinal changes early, before symptoms appear. When detected at an early stage, stopping the drug typically prevents further progression. This is why consistent screening matters even when you feel fine.
Dosing and Safety Limits
To minimize the risk of retinal damage, guidelines recommend keeping the daily dose at or below 5 mg per kilogram of your actual body weight. For someone weighing 70 kg (about 154 pounds), that means a maximum of 350 mg per day. This threshold was lowered from an earlier recommendation of 6.5 mg per kilogram of ideal body weight, reflecting updated evidence about long-term eye safety.
Your rheumatologist will typically start you at 200 to 400 mg daily, depending on your weight, and may adjust over time based on how well your disease responds and whether side effects emerge. Because the drug builds up slowly in your tissues, consistency matters more than any single dose. Missing a day here and there is unlikely to cause problems, but stopping for weeks at a time can set back your disease control.
Pregnancy and Hydroxychloroquine
Hydroxychloroquine is one of the few DMARDs considered compatible with pregnancy. Most rheumatology guidelines recommend continuing it during pregnancy and breastfeeding, since stopping it can trigger disease flares that themselves pose risks to both mother and baby. The drug does cross the placenta and passes into breast milk in small amounts, but decades of use have not shown increased rates of birth defects or developmental problems in exposed children.